前列康片治疗Ⅲ型前列腺炎的临床研究

Clinical efficacy of Qianliekang tablets on type Ⅲ prostatitis

目的评价前列康片对Ⅲ型前列腺炎的临床疗效。方法 105例Ⅲ型前列腺炎患者口服前列康片每次2 g,tid,服用6周,治疗前和治疗6周后进行慢性前列腺炎症状指数(NIH-CPSI)评分并复查前列腺液(EPS)血常规。结果治疗6周后,总有效率为84.3%;NIH-CPSI评分及EPS白细胞数目较治疗前均显著下降(P<0.05)。结论前列康片治疗Ⅲ型前列腺炎疗效确切。

Objective To evaluate the clinical efficacy of Qianliekang tablets on type Ⅲ prostatitis. Methods A total of 105 patients with typeⅢ prostatitis were enrolled in this study. All patients took 2 g Qianliekang tablets each time for 6 weeks,three times a day. With National Instituted of Health- chronic prostatitis symptom index（ NIH- CPSI） scores and expressed prostatic secretious（ EPS） as evaluating indexes,they were compared before and after treatment. Results The total effective rate of Qianliekang tablets was 84. 3% after six weeks of treatment. There were significant statistical differences in NIH- CPSI scores and the amount of leukocyte in EPS between before treatment and six weeks after treatment（ P〈0. 05）. Conclusion The results of this study have demonstrated that Qianliekang tablets has a definite clinical effect on treating type Ⅲ prostatitis.